Celgene, missed analysts' sales projections for the third quarter by 4%, cut its guidance for 2020 by 5% to 10%. Shares are down 17%. “Our assumptions just really missed the mark, particularly in this window,” said Mark Alles, the company’s chief executive, on a conference call.
